T. Rowe Price Associates
PBYI icon

T. Rowe Price Associates’s Puma Biotechnology PBYI Stock Holding History

T. Rowe Price Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Buy
31,306
+5,370
+21% +$34.6K ﹤0.01% 2842
2025
Q4 		$155K Buy
25,936
+4,311
+20% +$22.9K ﹤0.01% 2869
2025
Q3 		$115K Buy
21,625
+2,059
+11% +$8.73K ﹤0.01% 2898
2025
Q2 		$68K Hold
19,566
– – ﹤0.01% 2959
2025
Q1 		$58K Buy
19,566
+483
+3% +$1.51K ﹤0.01% 2908
2024
Q4 		$59K Buy
19,083
+5,726
+43% +$16.7K ﹤0.01% 2913
2024
Q3 		$35K Hold
13,357
– – ﹤0.01% 2963
2024
Q2 		$0 Buy
+13,357
New +$58.6K ﹤0.01% 2999
2022
Q4 		– Sell
-45,400
Closed -$108K – 2967
2022
Q3 		$108K Hold
45,400
– – ﹤0.01% 2710
2022
Q2 		$129K Sell
45,400
-2,868
-6% -$7.13K ﹤0.01% 2707
2022
Q1 		$139K Buy
48,268
+33,900
+236% +$87.7K ﹤0.01% 2791
2021
Q4 		$44K Sell
14,368
-300
-2% -$1.3K ﹤0.01% 2931
2021
Q3 		$103K Hold
14,668
– – ﹤0.01% 2841
2021
Q2 		$135K Buy
14,668
+643
+5% +$6.51K ﹤0.01% 2797
2021
Q1 		$136K Sell
14,025
-16
-0.1% -$179 ﹤0.01% 2755
2020
Q4 		$144K Buy
+14,041
New +$142K ﹤0.01% 2591
2020
Q3 		– Sell
-905,357
Closed -$9.44M – 2615
2020
Q2 		$9.44M Sell
905,357
-130,254
-13% -$1.35M ﹤0.01% 1306
2020
Q1 		$8.74M Buy
1,035,611
+349,305
+51% +$3.39M ﹤0.01% 1253
2019
Q4 		$6M Buy
686,306
+106,335
+18% +$880K ﹤0.01% 1371
2019
Q3 		$6.24M Buy
579,971
+81,362
+16% +$879K ﹤0.01% 1356
2019
Q2 		$6.34M Sell
498,609
-287,356
-37% -$6.62M ﹤0.01% 1371
2019
Q1 		$30.5M Buy
+785,965
New +$24M ﹤0.01% 1041
2018
Q3 		– Sell
-4,262
Closed -$252K – 2600
2018
Q2 		$252K Buy
4,262
+83
+2% +$4.81K ﹤0.01% 2399
2018
Q1 		$284K Sell
4,179
-1,972,338
-100% -$148M ﹤0.01% 2312
2017
Q4 		$195M Sell
1,976,517
-3,280,050
-62% -$367M 0.03% 465
2017
Q3 		$629M Buy
5,256,567
+1,822,895
+53% +$170M 0.11% 205
2017
Q2 		$300M Buy
3,433,672
+2,284,727
+199% +$128M 0.05% 346
2017
Q1 		$42.7M Buy
1,148,945
+470,510
+69% +$17.2M 0.01% 860
2016
Q4 		$20.8M Sell
678,435
-253,039
-27% -$10.9M ﹤0.01% 1131
2016
Q3 		$62.5M Sell
931,474
-85,400
-8% -$4.32M 0.01% 721
2016
Q2 		$30.3M Sell
1,016,874
-689,348
-40% -$21.6M 0.01% 955
2016
Q1 		$50.1M Sell
1,706,222
-13,390
-0.8% -$605K 0.01% 768
2015
Q4 		$135M Sell
1,719,612
-11,091
-0.6% -$871K 0.03% 481
2015
Q3 		$130M Sell
1,730,703
-363,744
-17% -$34.4M 0.03% 511
2015
Q2 		$245M Sell
2,094,447
-903,643
-30% -$164M 0.05% 392
2015
Q1 		$708M Buy
2,998,090
+231,389
+8% +$49.5M 0.15% 172
2014
Q4 		$524M Sell
2,766,701
-772,722
-22% -$171M 0.11% 217
2014
Q3 		$844M Buy
3,539,423
+329,056
+10% +$67.6M 0.18% 141
2014
Q2 		$212M Buy
3,210,367
+255,119
+9% +$18.1M 0.05% 422
2014
Q1 		$308M Buy
2,955,248
+8,724
+0.3% +$1.03M 0.07% 327
2013
Q4 		$305M Buy
2,946,524
+1,590,918
+117% +$93.4M 0.07% 323
2013
Q3 		$72.7M Sell
1,355,606
-22,961
-2% -$1.24M 0.02% 679
2013
Q2 		$61.2M Buy
+1,378,567
New +$48.6M 0.02% 717

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

T. Rowe Price Associates's PBYI Position: Q1 2026 in Review

T. Rowe Price Associates increased its Puma Biotechnology (PBYI) stake by 21% in Q1 2026, buying an estimated $34.6K and bringing the position to 31,306 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #2842.

T. Rowe Price Associates first reported a position in PBYI in Q2 2013 and has held it in 43 quarters since. The position peaked at $844M in Q3 2014. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • T. Rowe Price Associates held 31,306 shares of Puma Biotechnology worth $201K as of Q1 2026.
  • T. Rowe Price Associates bought 5,370 Puma Biotechnology shares in Q1 2026, an estimated $34.6K.
  • Puma Biotechnology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2842 holding.
  • T. Rowe Price Associates first reported a position in Puma Biotechnology in Q2 2013 and has held it in 43 quarters since.
  • T. Rowe Price Associates's Puma Biotechnology position peaked at $844M in Q3 2014.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.